May 17, 2017

7 Realities of Building an In-House Medical Device Development Team

In-house medical device development requires dedicated, highly skilled and experienced talent; acquisition of necessary equipment and facilities to build to feasibility and beyond; and sourcing and management of reliable partners for specialty materials, preclinical trials, and the regulatory process. As you are calculating the time it will take to bring your new team together, keep these realities in mind: What will it take to convince your first-pick hire to leave a job they already have? […]
May 4, 2017
REV.1 Engineering Medical Device Design

Medical Device Development with Advanced Materials

REV.1 recently had a client with a highly specialized wound care product which combined molded and converted parts. Careful sourcing was necessary to find the advanced materials necessary. The client had a difficult time finding the right firm with the capability to bring all the different resources required to move from concept to feasibility to successful product. REV.1 Engineering laid out a comprehensive product development program that included innovative bench models to vet prototypes and […]
April 27, 2017
REV.1 Engineering team at work.

The Value of 2x Faster Medical Device Development

You have that special “spark” of an idea, the one that excites and drives you and your colleagues to lay it all on the line to make it happen. Now you are on the clock. The time it takes to go from “spark” to approved medical device is a CEO’s biggest opportunity… and biggest threat. Reducing the amount of time it takes to get through each critical phase is what will build the highest value […]
April 24, 2017
REV.1 Engineering Medical Device

Medical Device Funding Confidence

Regardless of your stage or current structure, continued funding sources for medical device development are difficult to find. According to Price Waterhouse Coopers, funding for medical device companies dropped by $1 billion in 2009, and has been essentially flat ever since. Large investors want to come in late, after technical and clinical risks have been eliminated and market acceptance validated. The only way to secure continued confidence and funding is to prove to your investors […]